Browsing by Author "Dalmases Massegú, Alba, 1982-"

Sort by: Order: Results:

  • Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
    Casadevall Aguilar, David; Vidal Barrull, Joana; Gallardo Hernández, Fernando; Zuccarino, Flavio; Arumí, Montserrat; Dalmases Massegú, Alba, 1982-; Bellosillo Paricio, Beatriz; Montagut Viladot, Clara (BioMed Central, 2016)
    BACKGROUND: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90-95 ...
  • Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
    Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations
    Brammeld, Jonathan S.; Dalmases Massegú, Alba, 1982-; Bellosillo Paricio, Beatriz; Vidal Barrull, Joana; Montagut Viladot, Clara; McDermott, Ultan (Cold Spring Harbor Laboratory Press (CSHL Press), 2017)
    Drug resistance is an almost inevitable consequence of cancer therapy and ultimately proves fatal for the majority of patients. In many cases, this is the consequence of specific gene mutations that have the potential to ...
  • HER-family ligands promote acquired resistance to trastuzumab in gastric cancer
    Sampera Borràs, Aïda, 1990-; Sánchez-Martín, Francisco Javier; Arpí Llucià, Oriol; Visa Turmo, Laura; Iglesias Coma, Mar; Menéndez, Silvia; Gaye, Élisabeth; Dalmases Massegú, Alba, 1982-; Clavé Safont, Sergi; Gelabert-Baldrich, Mariona; Tuxen Poulsen, Thomas; Kragh, Michael; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Rovira Guerín, Ana; Rovira Guerín, Ana; Montagut Viladot, Clara (American Association for Cancer Research (AACR), 2019)
    Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer ...
  • Inhibition of specific NF-KB activity contributes to the tumor suppressor function of 14-3-3omega in breast cancer
    Inglés Esteve, Julia; Morales, Mònica; Dalmases Massegú, Alba, 1982-; Garcia Carbonell, Ricard; Jené i Sanz, Alba, 1984-; López Bigas, Núria; Iglesias Coma, Mar; Ruiz Herguido, Cristina; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; Gomis, Roger R.; Bigas Salvans, Anna; Espinosa Blay, Lluís (Public Library of Science (PLoS), 2012)
    14-3-3σ is frequently lost in human breast cancers by genetic deletion or promoter methylation. We have now investigated the involvement of 14-3-3σ in the termination of NF-κB signal in mammary cells and its putative role ...
  • The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
    Sanchez Martin, Francisco Javier; Bellosillo Paricio, Beatriz; Gelabert-Baldrich, Mariona; Dalmases Massegú, Alba, 1982-; Cañadas Castillo, Israel, 1984-; Vidal Barrull, Joana; Martinez, Alejandro; Argiles, Guillem; Visa Turmo, Laura; Arpí Llucià, Oriol; Iglesias García, Mar; Rovira Guerín, Ana; Albanell Mestres, Joan; Tabernero Cartula, Josep; Montagut Viladot, Clara (American Association for Cancer Research, 2016)
    PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking